Molecular neurobiology of the cannabinoid receptor

International Review of Neurobiology

Volumn 39, Issue 39, 1996, Pages 197-221

  Abood, Mary E ^a   Martin, Billy R ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABINOID; CANNABINOID RECEPTOR; DRUG RECEPTOR; LIGAND;

AMINO ACID SEQUENCE; ANIMAL; BRAIN LEVEL; DRUG EFFECT; HUMAN; MOLECULAR CLONING; MOLECULAR GENETICS; PHYSIOLOGY; REVIEW;

AMINO ACID SEQUENCE; ANIMALS; BRAIN CHEMISTRY; CANNABINOIDS; CLONING, MOLECULAR; HUMANS; LIGANDS; MOLECULAR SEQUENCE DATA; RECEPTORS, CANNABINOID; RECEPTORS, DRUG;

EID: 0030333234     PISSN: 00747742     EISSN: None     Source Type: Book Series    
DOI: 10.1016/s0074-7742(08)60667-4     Document Type: Article

References (99)

1. Abadji, V., Lin, S., Taha, G., Grifin, G., Stevenson, L. A., Pertwee, R. G., and Makriyannis, A. (1994). (R)-Methanandamide: A chiral novel anandamide possessing higher potency and metabolic stability. J. Med. Chem. 37, 1889-1893.
2. Abood, M. E., Sauss, C., Fan, F., Tilton, C. L., and Martin, B. R. (1993). Development of behavioral tolerance to A9-THC without alteration of cannabinoid receptor binding or mRNA levels in whole brain. Pharmacol. Biochem. Behav. 46, 575-579.
3. Aceto, M. D., Scales, S. M., Lowe, J. A., and Martin, B. R. (1995). Cannabinoid precipitated withdrawal by the selective cannabinoid receptor antagonist, SR 141716A. Eur.J. Pharmacol. 282, R1-R2.
4. Adams, I. B., Ryan, W., Singer, M., Razdan, R. K., Compton, D. R., and Martin, B. R. (1995a). Pharmacological and behavioral evaluation of alkylated anandamide analogs. Life Sci. 56, 2041-2048.
5. Adams, I. B., Ryan, W., Singer, M., Thomas, B. F., Compton, D. R., Razdan, R. K., and Martin, B. R. (1995b). Evaluation of cannabinoid receptor binding and in vivo activities for anandamide analogs.J. Pharmacol. Exp. Ther. 273, 1172-1181.
6. Barg, J., Fride, E., Hanus, L., Levy, R., Matus-Leibovitch, N., Heldman, E., Bayewitch, M., Mechoulam, R., and Vogel, Z. (1995). Cannabimimetic behavioral effects and adenylate cyclase inhibition by two new endogenous anandamides. Eur.J. Pharmacol. 287, 145-152.
7. Bayewitch, M., Avidor-Reiss, T., Levy, R., Barg, J., Mechoulam, R., and Vogel, Z. (1995). The peripheral cannabinoid receptor: Adenylate cyclase inhibition and G protein coupling. FEBS Lett. 375, 143-147.
8. Belue, R. C., Hewlett, A. C.,WestIake, T. M., and Hutchings, D. E. (1995). The ontogeny of cannabinoid receptors in the brain of postnatal and aging rats. Neurotoxicol. Teralol. 17, 25-30.
9. Bidaut-Russell, M., and Howlett, A. C. (1991). Cannabinoid receptor-regulated cyclic AMP accumulation in the rat striatum.J. Neurochem. 57, 1769-1773.
10. Bouaboula, M., Rinaldi, M., Carayon, P., Carillon, C., Delpech, B., Shire, D., Le Fur, G., and Casellas, P. (1993). Cannabinoid-receptor expression in human leukocytes. Eur.J. Biochem. 214, 173-180.
11. Bramblett, R. D., Panu, A. M., Ballesteros, J. A., and Reggio, P. H. (1995). Construction of a 3D model of the cannabinoid CB1 receptor: Determination of helix ends and helix orientation. Life Sci. 56, 1971-1982.
12. Burstein, S. H. (1987). Inhibitory and stimulatory effects of cannabinoids on eicosanoid synthesis. In "Structure-Activity Relationships of the Cannabinoids," NIDA Research Monograph Series No. 79 (R. A. Rapaka, and A. Makriyannis, eds.), pp. 158-172. U.S. Government Printing Office, Washington, D.C.
13. 9-Tetrahydrocannabinoal decreases α/β-interferon response to herpes simplex virus type 2 in the B6C3F1 mouse. Proc. Soc. Exp. Biol. Med. 181, 305-311.
14. Collins, S., Caron, M. G., and Lefkowitz, R. G. (1992). From ligand binding to gene expression: New insights into the regulation of G-protein-coupled receptors. Trends Biochem. Sci. 17, 37-39.
15. Compton, D. R., Dewey, W. L., and Martin, B. R. (1990). Cannabis dependence and tolerance production. In "Addiction Potential of Abused Drugs and Drug Classes" (C. K. Erickson, M. A.Javors, and W. W. Morgan, eds.), pp. 128-147. The Hayworth Press, Inc., Binghampton, N.Y.
16. Compton, D. R., Johnson, M. R., Melvin, L. S., and Martin, B. R. (1991). Pharmacological evaluation of a series of bicyclic cannabinoid analogs: Classification as cannabimimetic agents.J. Pharmacol. Exp. Ther. 260, 201-209.
17. Compton, D. R., Rice, K. C., De Costa, B. R., Razdan, R. K., Melvin, L. S., Johnson, M. R., and Martin, B. R. (1993). Cannabinoid structure-activity relationships: Correlation of receptor binding and in vivo activities.J.Pharmacol. Exp. Ther. 265, 218-226.
18. Crawley, J., Corwin, R., Robinson, J., Felder, C., Devane, W., and Axelrod, J. (1993). Anandamide, an endogenous ligand of the cannabinoid receptor, induces hypomotility and hypothermia in vivo in rodents. Pharmacol. Biochem. Behav. 46, 967-972.
19. Creese, I., and Sibley, D. (1981). Receptor adaptations to centrally acting drugs. Annu. Rev. Pharm. Tax. 21, 357-391.
20. Daaka, Y., Klein, T. W., and Friedman, H. (1995). Expression of cannabinoid receptor mRNA in murine and human leukocytes. In "The Brain Immune Axis and Substances Abuse" (B. Sharp, T. Eisenstein, J. Madden, and H. Friedman, eds.), pp. 91-96. Plenum Press, New York.
21. Das, S. K., Paria, B. C., Chakraborty, I., and Dey, S. K, (1995). Cannabinoid ligand-receptor signaling in the mouse uterus. Proc. Natl. Acad. Sei. USA 92, 4332-4336.
22. Derocq,J.-M., and Segui, M., Marchand, J., Fur, G. L., and Casellas, P. (1995). Cannabinoids enhance human B-cell growth at low nanomolar concentrations. FEBS foil. 369,177-182.
23. Deutsch, D. G., and Chin, S. A. (1993). Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist. Biochem. Pharmacol. 46, 791-796.
24. Devane, W. A., and Axelrod, J. (1994). Enzymatic synthesis of anandamide, an endogenous ligand for the cannabinoid receptor, by brain membranes. Proc. Natl. Acad. Sei. USA 91, 6698-6701.
25. Devane, W. A., Dysarz, I. F. A., Johnson, M. R., Melvin, L. S., and Howlett, A. C. (1988). Determination and characterization of a cannabinoid receptor in rat brain. Mol. Pharmacol. 34, 605-613.
26. Devane, W. A., Hanus, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A., and Mechoulam, R. (1992). Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258, 1946-1949.
27. Dewey, W. L. (1986). Cannabinoid pharmacology. Pharmacol. Rev. 38, 151-178.
28. Dill, J. A., and Howlett, A. C. (1988). Regulation of adenylate cyclase by chronic exposure to cannabimimetic drugs. J. Pharmacol. Exp. Ther. 244, 1157-1163.
29. DiMarzo, V., Fontana, A., Cadas, H., Schinelli, S., Cimino, G., Schwartz, J.-C., and Piomelli, D. (1994). Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 372, 686-691.
30. Facci, L., Toso, R. D., Romanello, S., Buriani, A., Skaper, S. D., and Leon, A. (1995). Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc. Nail. Acad. Sei. USA 92, 3376-3380.
31. Fan, F., Compton, D. R., Ward, S., Melvin, L., and Martin, B. R. (1994). Development of cross-tolerance between Δ9-THC, CP 55,940 and WIN 55,212. J. Pharmacol. Exp. Ther. 271, 1383-1390.
32. Fan, F., Tao, Q, Abood, M., and Martin, B. R. (1996). Cannabinoid receptor down-regulation without alteration of the inhibitor)' effect of CP 55,940 on adenylyl cyclase in the cerebellum of CP 55,940-tolerant mice. Brain Res. 706, 13-20.
33. Felder, C. C., Veluz, J. S., Williams, H. L., Briley, E. M.,and Matsuda, L. A. (1992). Cannabinoid agonists stimulate both receptor- and non-receptor-mediated signal transduction pathways in cells transfected with and expressing Cannabinoid receptor clones. Mol. Pharmacol. 42, 838-845.
34. Felder, C. C., Briley, E. M., Axelrod, J., Simpson, J. T., Mackie, K., and Devane, W. A. (1993). Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned human Cannabinoid receptor and stimulates receptor-mediate signal transduction. Proc. Natl. Acad. Set. USA 90, 7656-7660.
35. Felder, C. C., Joyce, K. E., Briley, E. M., Mansouri, J., Mackie, K., Blond, O., Lai, Y., Ma, A. L., and Mitchell, R. L. (1995). Comparison of the pharmacology and signal transduction of the human Cannabinoid CB1 and CB2 receptors. Mol. Phannacol. 48, 443-450.
36. Fontana, A., DiMarzo, V., Cadas, H., and Piomelli, D. (1995). Analysis of anandamide, an endogenous Cannabinoid substance, and of other natural N-acylethanolamines. Prostaglandins Leukot. Essent. Fatty Adds 53, 301-308.
37. 9-tetrahydrocannabinol. Brain Res. 697, 83-90.
38. Fride, E., and Mechoulam, R. (1993). Pharmacological activity of the Cannabinoid receptor agonist, anandamide, a brain constituent. Eur.J. Pharmacol. 231, 313-314.
39. Friedman, H., Shivers, S. C., and Klein, T. W. (1994). Drugs of abuse and the immune system. In "Immunotoxicology and immunopharmacology" (J. H. Dean, M. I. Luster, A. E. Munson, and I. Kimber, eds.), pp. 303-322. Raven Press, New York.
40. Galiegue, S., Mary, S., Marchand, J., Dussossoy, D., Carriere, D., Carayon, P., Bouaboula, M., Shire, D., LeFur, G., and Casellas, P. (1995). Expression of central and peripheral Cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur. J. Biochem. 232, 54-61.
41. Gerard, C. M., Mollereau, C., Vassart, G., and Parmentier, M. (1991). Molecular cloning of a human Cannabinoid receptor which is also expressed in testis. Biochem.J, 279, 129-134.
42. Glass, M., and Dragimow, M. (1995). Induction of the Krox 24 transcription factor in striosomes by a Cannabinoid agonist. Neuroreport 6, 241-244.
43. Hadcock.J. R., and Malbon, C. C. (1991). Regulation of receptor gene expression by agonists: Transcriptional and post-transcriptional controls. Trends Neurosci. 14, 242-247.
44. Hanus, L., Gopher, A., Almog, S., and Mechoulam, R. (1993). Two new unsatiirated fatty acid ethanolamides in brain that bind to the Cannabinoid receptor J. Med. Chem.36,3032-3034.
45. Herkenham, M., Lynn, A. B., Little, M. D., Johnson, M. R., Melvin, L. S., DeCosta, B. R., and Rice, K, C. (1990). Cannabinoid receptor localization in the brain. Proc. Natl. Acad. Sei. USA 87, 1932-1936.
46. Herkenham, M., Lynn, A. B., deCosta, B. R., and Richfield, E. K. (1991). Neuronal localization of Cannabinoid receptors in the basal ganglia of the rat. Brain Res. 547, 267-274.
47. Herkenham, M., Lynn, A. B., Johnson, M. R., Melvin, L. S., de Costa, B. R., and Rice, K. C. (1991b). Characterization and localization of Cannabinoid receptors in rat brain: A quantative in vitro autographic study.J. Neurosci. 11, 563-583.
48. Hollister, L. E. (1986). Health aspects of cannabis. Phannacol. Rev. 38, 1-20.
49. Howlett, A. C. (1995). Pharmacology of Cannabinoid receptors. Ann. Rev. Phannacol. Toxicol. 35, 607-634.
50. Howlett, A. C., and Fleming, R. M. (1984). Cannabinoid inhibition of adenylate cyclase: Pharmacology of the response in neuroblastoma cell membranes. Mol. Pharmacol. 26, 532-538.
51. Kaminski, N. E., Abood, M. E., Kessler, F. K., Martin, B. R., and Schatz, A. R. (1992). Identification of a functionally relevant cannabinoid receptor on mouse spleen cells that is involved in cannabinoid-mediated immune modulation. Mol. Pharmacol. 42, 736-742.
52. Kruszka, K., and Gross, R. (1994). The ATP-and CoA-independent synthesis of arachidonoylethanolamide.J. Biol. Chem. 269, 14345-14348.
53. Law, P. Y., Horn, D. S., and Loh, H.H. (1982). Loss of opiate receptor activity in neuroblastoma x glioma NG108-15 hybrid cells after chronic opiate treatment. Mol. Pharmacol. 22, 1-4.
54. Law, P. Y., Horn, D. S., and Loh, H. H. (1983). Opiate receptor down-regulation and desensitization in neuroblastoma x glioma hybrid cells are two separate processes. Mol. Pharmacol. 24, 413-424.
55. Lohse, M. J. (1993). Molecular mechanisms of membrane receptor desensitization. Biochim. Biophys. Ada. 1179, 171-188.
56. Lynn, A. B., and Herkenham, M. (1994). Localization of cannabinoid receptors and nonsaturable high-density cannabinoid binding sites in peripheral tissues of the rat: Implications for receptor-mediated immune modulation by cannabinoids. J. Pharmacol. Exp. Ther. 268, 1612-1623.
57. Mackie, K., and Hille, B. (1992). Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. Proc. Nail. Acad. Set. USA 89, 3825-3829.
58. Mackie, K., Devane, W., and Hille, B. (1993). Anandamide, an endogenous cannabinoid, inhibits calcium currents as a partial agonist in N18 neuroblastoma cells. Mol. Pharmacol 44, 498-503.
59. Mackie, K., Lai, Y, Westernbroek, R., and Mitchell, R. (1995). Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with the rat brain cannabinoid receptor.J. Neurosci. 15, 6552-6561.
60. Mailleux, P., and Vanderhaeghen, J.J. (1992). Distribution of neuronal cannabinoid receptor in the adult rat brain: A comparative receptor binding radioautography and in silu hybridization histochemistry. Neuroscience 48, 655-668.
61. Mailleux, P., and Vanderhaeghen, J.-J. (1993a). Dopaminergic regulation of cannabinoid receptor mRNA levels in the rat caudate-putamen: An in situ hybidization study.J. Neurochem. 61, 1705-1712.
62. Mailleux, P., and Vanderhaeghen, J.J. (1993b). Glucocorticoid regulation of cannabinoid receptor messenger RNA levels in the rat caudate-putamen: An in situ hybridization study. Neurosci. Lett. 156, 51-53.
63. Mailleux, P., and Vanderhaeghen.J.J. (1994). Glutamergic regulation of cannabinoid receptor gene expression in the caudate-putamen. Eur.J. Pharmacol.-Mol. Pharmacol. 266, 193-196.
64. Martin, B. R. (1986). Cellular effects of cannabinoids. Pharmacol. Rev. 38, 45-74.
65. Martin, B. R.,Dewey.W.L.,Harris, L. S.,andBeckner.J.S. (1976). 3H-Δ9-tetrahydrocannabinol tissue and subcellular distribution in the central nervous system and tissue distribution in peripheral organs of tolerant and nontolerant dogs.J. Pharmacol. Exp. Ther. 196, 128-144.
66. Matsuda, L. A., Lolait, S. J., Brownstein, M. J., Young, A. C., and Bonner, T. I. (1990). Structure of a cannabinoid receptor and functional expression of the cloned cDN'A. Nature 346, 561-564.
67. Matsuda, L. A., Bonner, T. I., and Lolait, S. J. (1993). Localization of cannabinoid receptor mRNA in rat brain.J. Camp. Neural. 327, 535-550.
68. McLaughlin, C. R., and Abood, M. E. (1993). Developmental expression of cannabinoid receptor mRNA. Develop. Brain Res. 76, 75-78.
69. McLaughlin, C. R., Dewey, W. L., and Abood, M. E. (1992). Developmental expression of cannabinoid receptor mRNA. Soc. Neurosci. Abs. 18, 1539.
70. McLaughlin, C. R., Martin, B. R., Compton, D. R., and Abood, M. E. (1994). Cannabinoid receptors in developing rats: Detection of mRNA and receptor binding. Durg Alcohol Depend. 36, 27-31.
71. McMillan, D. E., Dewey, W. L., and Harris, L. S. (1971). Characteristics of tetrahydrocannibinol tolerance. Ann. N.Y. Acad. Sei. 191, 83-99.
72. Mechoulam, R., and Fride, E. (1995). The unpaved road to the endogenous cannabinoid ligand anandamide. In "Cannabinoids" (R. G. Pertwee, éd.), pp. 233-258. Academic Press, London.
73. Mechoulam, R., Ben-Shabat, S., Hanus, L., Ligumsky, M., Kaminski, N. E., Schatz, A. R., Gopher, A., Almog, S., Martin, B. R., Compton, D. R., Pernvee, R. G., Griffin, G., Bayewitch, M., Barg, J., and Vogel, Z. (1995). Identification of an endogenous 2-monogIyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol. 50, 83-90.
74. Morris, B.J. (1993). Control of receptor sensitivity at the mRNA level. Mol. Neurobiol. 7,189-205.
75. Munro, S. .Thomas, K.L., and Abu-Shaar, M. (1993). Molecular characterization of a peripheral receptor for cannabinoids. Nature 365, 61-65.
76. Oviedo, A., Glowa, J., and Herkenham, M. (1993). Chronic cannabinoid administration alters cannabinoid receptor binding in rat brain: A quantitative autoradiographic study. Brain Res. 616, 293-302.
77. Pernvee, R. G. (1991). Tolerance to and dependence on psychotropic cannabinoids. In "The Biological Basis of Drug Tolerance and Dependence" (J. A. Pratt, éd.), pp. 231-263. Academic Press, New York.
78. Pernvee, R. G. (1995). Cannabinoid Receptors. Academic Press, London.
79. Razdan, R. K. (1986). Structure-activity relationships in cannabinoids. Pharmacol. Rev. 38, 75-149.
80. Rinaldi-Carmona, M., Barth, F., Heaulme, M., Shire, D., Calandra, B., Congy, C., Martinez, S., Maruani, J., Neliat, G., Caput, D., Ferrar, P., Soubrie, P., Breliere, J. C., and Fur, G. L. (1994). SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. 350, 240-244.
81. Rodriguez-de-Fonseca, F., Ramos.J. A., Bonnin, A., and Fernandez-Ruiz.J.J. (1993). Presence of cannabinoid binding sites in the brain from early postnatal ages. Neuroreport 4,135-138.
82. Rodriguez-de-Fonseca, F., Gorriti, M., Fernandez, R. J., Palomo, T., and Ramos, J. A. (1994). Down regulation of rat brain cannabinoid binding sites after chronic Δ9-tetrahydrocannabinol treatment. Pharmacol. Biochem. Behav. 47, 33-40.
83. Romero, J., de Miguel, R., García-Palomero, E., Fernández-Ruiz.J.J., and Ramos,J. A. (1995). Time-course of the effects of anandamide, the putative endogenous cannabinoid receptor ligand, on extrapyramidal function. Brain Res. 694, 223-232.
84. Scarpace, P. J., and Abrass, I. B. (1982). Desensitization of adenylate cyclase and down regulation of beta adrenergic receptors after in vivo administration of beta agonist. J. Pharmacol. Exp. Ther. 327-331.
85. Schatz, A. R., Kessler, F. K., and Kaminski, N. E. (1992). Inhibition of adenylate cyclase by Δ9-tetrahydrocannibinol in mouse spleen cells: A potential mechanism for cannabinoidmediated immunosuppression. Life Sei. 51, 25-30.
86. Shire, D., Carillon, C., Kaghad, M., Calandra, B., Rinaldi-Carmona, M., Fur, G. L., Caput, D., and Ferrara, P. (1995). An amino-terminal variant of the central cannabinoid receptor resulting from alternative splicing. J. Biol. Chem. 270, 3726-3731.
87. Shivachar, A. C., Martin, B. R., and Ellis, E. F. (1996). Anandamide-evoked arachidonic acid mobilization and blockade by SR 141716A [N-(piperidin-l-yl)-5-4(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH- pyrazole-3-carboximide hydrochloride]. Biochem. Pharmacol. 51, 669-676.
88. Showalter, V. M., Compton, D. R., Martin, B. R., and Abood, M. E. Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): Identification of cannabinoid receptor subtype selective ligands. J. Pharmacol. Exp. Ther. In press.
89. Slipetz, D. M. O'Neill, G. P., Favreau, L., Dufresne, C., Gallant, M., Gareau, Y., Guay, D., Labelle, M., and Metters, K. M. (1995). Activation of the human peripheral cannabinoid receptor results in inhibition of adenylyl cyclase. Mol. Pharmacol. 48, 352-361.
90. Smith, P. B., Compton, D. R., Welch, S. P., Razdan, R. K., Mechoulan, R., and Martin, B. R. (1994). The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice. J. Pharmacol. Exp. Ther.270, 219-227.
91. Thomas, B. R., Adams, I. B., Mascarella, S. W., Martin, B. R., and Razdan, R. K. (1996). Conformational analysis of anandamide analogs: Relationship to a cannabinoid pharmacophore. J. Med. Chem. 39, 471-479.
92. 9-tetrahydrocannabinol precipitated by a cannabinoid receptor antagonist. Eur.J. Pharmacol. 280, R13-R15.
93. Venance, L., Piomelli, D., Glowinski, J., and Giaume, C. (1995). Inhibition by anandamide of gap junctions and intercellular calcium signalling in striatal astrocytes. Nature 376, 590-594.
94. Vogel, Z., Barg, J., Levy, R., Saya, D., Heldman, E., and Mechoulam, R. (1993). Anandamide, a brain endogenous compound, interacts specifically with cannabinoid receptors and inhibits adenylate cyclase. J. Neurochem. 61, 352-355.
95. Weidenfeld, J., Feldman, S., and Mechoulam, R. (1994). The effect of the brain constituent anandamide, a cannabinoid receptor agonist, on the hypotholamo-pituitary-adrenal axis in the rat. Neuroendocrinol. 59, 110-112.
96. Werling, L. L., McMahon, P. N., and Cox, B. M. (1989). Selective changes in [n. opioid receptor properties induced by chronic morphine exposure. Proc. Natl. Acad. Sei. USA 86, 6393-6397.
97. 9-Tetrahydrocannabinol and anandamide enhance the ability of muscimol to induce catalepsy in the globus pallidus of rats. Eur.J. Pharmacol. 250, 205-208.
98. Wiley, J. L., Barrett, R. L., Lowe.J., Balster, R. I.., and Martin, B. R. (1995). Discriminative stimulus effects of CP 55,940 and structurally dissimilar cannabinoids in rats. Neurophannacology 34, 669-676.
99. 9-Tetrahydrocannabinol enhances the secreation of interleukin 1 from endotoxin-stimulated macrophages. J. Pharmacol. Exp. Ther. 270, 1334-1339.